Plasma cardiotrophin-1 levels are associated with hypertensive heart disease: A meta-analysis

Journal of Clinical Hypertension

Volumn 16, Issue 9, 2014, Pages 686-692

  Song, Kangxing ^a,b   Wang, Shuxia ^a,b   Huang, Bihui ^a   Luciano, Amelia ^a   Srivastava, Roshni ^a   Mani, Arya ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOTROPHIN 1; BIOLOGICAL MARKER; CYTOKINE;

CARDIOVASCULAR RISK; CONGESTIVE CARDIOMYOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; ADOLESCENT; ADULT; AGED; BLOOD; CARDIOMEGALY; CASE CONTROL STUDY; COMPLICATION; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; PREDICTIVE VALUE; PROSPECTIVE STUDY; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CARDIOMEGALY; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84907963375     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12376     Document Type: Review

References (41)

1. Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from HHF registries. J Am Coll Cardiol. 2014;63:1123-1133.
2. Chockalingam A. World hypertension day and global awareness. Can J Cardiol. 2008;24:441-444.
3. Azad N, Kathiravelu A, Minoosepeher S, et al. Gender differences in the etiology of heart failure: a systematic review. J Geriatr Cardiol. 2011;8:15-23.
4. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8:30-41.
5. Izzo JL Jr, Gradman AH. Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure. Med Clin North Am. 2004;88:1257-1271.
6. Gradman AH, Alfayoumi F. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis. 2006;48:326-341.
7. Gluba A, Bielecka-Dabrowa A, Mikhailidis DP, et al. An update on biomarkers of heart failure in hypertensive patients. J Hypertens. 2012;30:1681-1689.
8. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-1847.
9. Oikonomou E, Tousoulis D, Siasos G, et al. The role of inflammation in heart failure: new therapeutic approaches. Hellenic J Cardiol. 2011;52:30-40.
10. Jougasaki M. Cardiotrophin-1 in cardiovascular regulation. Adv Clin Chem. 2010;52:41-76.
11. Gonzalez A, Lopez B, Ravassa S, et al. Cardiotrophin-1 in hypertensive heart disease. Endocrine. 2012;42:9-17.
12. Calabro P, Limongelli G, Riegler L, et al. Novel insights into the role of cardiotrophin-1 in cardiovascular diseases. J Mol Cell Cardiol. 2009;46:142-148.
13. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603-605.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
16. Robador PA, Moreno MU, Beloqui O, et al. Protective effect of the 1742(c/g) polymorphism of human cardiotrophin-1 against left ventricular hypertrophy in essential hypertension. J Hypertens. 2010;28:2219-2226.
17. Zolk O, Ng LL, O'Brien RJ, et al. Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance. Circulation. 2002;106:1442-1446.
18. Khan SQ, Kelly D, Quinn P, et al. Cardiotrophin-1 predicts death or heart failure following acute myocardial infarction. J Card Fail. 2006;12:635-640.
19. Celik A, Sahin S, Koc F, et al. Cardiotrophin-1 plasma levels are increased in patients with diastolic heart failure. Med Sci Monit. 2012;18:Cr25-Cr31.
20. Talwar S, Squire IB, O'Brien R J, et al. Plasma cardiotrophin-1 following acute myocardial infarction: relationship with left ventricular systolic dysfunction. Clin Sci (Lond). 2002;102:9-14.
21. Moreno MU, Jose GS, Pejenaute A, et al. Association of phagocytic NADPH oxidase activity with hypertensive heart disease: a role for cardiotrophin-1? Hypertension. 2014;63:468-474.
22. Ravassa S, Beloqui O, Varo N, et al. Association of cardiotrophin-1 with left ventricular systolic properties in asymptomatic hypertensive patients. J Hypertens. 2013;31:587-594.
23. Pemberton CJ, Raudsepp SD, Yandle TG, et al. Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. Cardiovasc Res. 2005;68:109-117.
24. Gkaliagkousi E, Gavriilaki E, Nikolaidou B, et al. Association between cardiotrophin 1 levels and central blood pressure in untreated patients with essential hypertension. Am J Hypertens. 2014;27:651-655.
25. Gonzalez A, Lopez B, Martin-Raymondi D, et al. Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. J Hypertens. 2005;23:2297-2304.
26. Lopez B, Castellano JM, Gonzalez A, et al. Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension. Hypertension. 2007;50:977-983.
27. Monserrat L, Lopez B, Gonzalez A, et al. Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. Eur Heart J. 2011;32:177-183.
28. Tsutamoto T, Wada A, Maeda K, et al. Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001;38:1485-1490.
29. Lopez B, Gonzalez A, Querejeta R, et al. Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: potential diagnostic implications. J Hypertens. 2009;27:418-424.
30. Limongelli G, Roselli T, Pacileo G, et al. Effect of cardiac resynchronization therapy on cardiotrophin-1 circulating levels in patients with heart failure. Intern Emerg Med. 2014;9:43-50.
31. Talwar S, Downie PF, Squire IB, et al. An immunoluminometric assay for cardiotrophin-1: a newly identified cytokine is present in normal human plasma and is increased in heart failure. Biochem Biophys Res Commun. 1999;261:567-571.
32. Gonzalez A, Ravassa S, Loperena I, et al. Association of depressed cardiac gp130-mediated antiapoptotic pathways with stimulated cardiomyocyte apoptosis in hypertensive patients with heart failure. J Hypertens. 2007;25:2148-2157.
33. Ng LL, O'Brien RJ, Demme B, Jennings S. Non-competitive immunochemiluminometric assay for cardiotrophin-1 detects elevated plasma levels in human heart failure. Clini Sci (Lond). 2002;102:411-416.
34. Talwar S, Squire IB, Downie PF, et al. Elevated circulating cardiotrophin-1 in heart failure: relationship with parameters of left ventricular systolic dysfunction. Clin Sci (Lond). 2000;99:83-88.
35. Cottone S, Nardi E, Mule G, et al. Association between biomarkers of inflammation and left ventricular hypertrophy in moderate chronic kidney disease. Clin Nephrol. 2007;67:209-216.
36. Lopez B, Gonzalez A, Querejeta R, et al. Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure. Hypertension. 2014;63:483-489.
37. Lopez B, Gonzalez A, Lasarte JJ, et al. Is plasma cardiotrophin-1 a marker of hypertensive heart disease? J Hypertens. 2005;23:625-632.
38. Tsutamoto T, Asai S, Tanaka T, et al. Plasma level of cardiotrophin-1 as a prognostic predictor in patients with chronic heart failure. Eur J Heart Fail. 2007;9:1032-1037.
39. Hishinuma S, Funamoto M, Fujio Y, et al. Hypoxic stress induces cardiotrophin-1 expression in cardiac myocytes. Biochem Biophys Res Commun. 1999;264:436-440.
40. Railson JE, Liao Z, Brar BK, et al. Cardiotrophin-1 and urocortin cause protection by the same pathway and hypertrophy via distinct pathways in cardiac myocytes. Cytokine. 2002;17:243-253.
41. Lopez N, Diez J, Fortuno MA. Characterization of the protective effects of cardiotrophin-1 against non-ischemic death stimuli in adult cardiomyocytes. Cytokine. 2005;30:282-292.